Vivace Formalizes Leadership Ahead of Phase III

Company: Vivace Therapeutics · Event Type: Leadership Transition · New CEO: Craig Gibbs · Lead Program: VT3989 (Mesothelioma) · Date: August 26, 2026 Summary Vivace Therapeutics named Craig Gibbs as chief executive officer and appointed Ellen Lubman as chief business and strategy officer, formalizing a…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Ipsen Acquires Kartos Therapeutics for Up to $1.75B
Kuva Merger Collapse Forces Lisata Therapeutics Retrenchment
Gilead – $5B Tubulis Acquisition
Scribe Sets Terms for a $100 Million IPO